34841-55-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-amino-2-methylphenyl)acetic acid is used as an analgesic and anti-inflammatory agent for the treatment of arthritis and other inflammatory conditions. It is effective in alleviating symptoms such as inflammation, swelling, stiffness, and joint pain by inhibiting the production of prostaglandins.
Used in Pain Management:
As a nonsteroidal anti-inflammatory drug, 2-(4-amino-2-methylphenyl)acetic acid is used for pain management, specifically in conditions where inflammation is a contributing factor, such as in arthritis.
Used in Anti-inflammatory Therapy:
In the context of anti-inflammatory therapy, 2-(4-amino-2-methylphenyl)acetic acid serves to reduce inflammation by targeting the biochemical pathways that lead to the synthesis of prostaglandins, thus providing relief from the associated discomfort and swelling.

InChI:InChI=1/C9H11NO2/c1-6-4-8(10)3-2-7(6)5-9(11)12/h2-4H,5,10H2,1H3,(H,11,12)

Upstream product

• 34956-30-4 N-(3-methyl-4-(2-(4-morpholinyl)-2-thioxoethyl)phenyl)acetamide 
• 34956-31-5 N-(4-acetyl-3-methylphenyl)acetamide 

Downstream Products

• 1374573-70-2 [2-methyl-4-(1H-tetrazol-1-yl)phenyl]acetic acid 
• 50712-55-5 ethyl 2-(4-amino-2-methylphenyl)acetate 

Relevant academic research and scientific papers

Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists

Activation of the nuclear farnesoid X receptor (FXR) which acts as cellular bile acid sensor has been validated as therapeutic strategy to counter liver disorders such as non-alcoholic steatohepatitis by the clinical efficacy of obeticholic acid. FXR antagonism, in contrast, is less well studied and potent small molecule FXR antagonists are rare. Here we report the systematic optimization of a novel class of FXR antagonists towards low nanomolar potency. The most optimized compound antagonizes baseline and agonist induced FXR activity in a full length FXR reporter gene assay and represses intrinsic expression of FXR regulated genes in hepatoma cells. With this activity and a favorable toxicity-, stability- and selectivity-profile it appears suitable to further study FXR antagonism in vitro and in vivo.

TRIAZOLOPYRIDAZINE DERIVATIVES

The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R3' are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula (I).